Are patients ready to participate in diet intervention trials in oncology? Experience from renal cell carcinoma (RCC) patients.

Authors

null

Emeline Colomba

Gustave Roussy Cancer Campus, Paris Saclay University, Villejuif, France

Emeline Colomba , Bruno Raynard , Annalisa Guida , Lisa Derosa , Bernard Escudier , Laurence Albiges

Organizations

Gustave Roussy Cancer Campus, Paris Saclay University, Villejuif, France, Gustave Roussy, Villejuif, France, Institut Gustave Roussy, Villejuif, France, U1015 INSERM, Gustave Roussy Cancer Campus, Paris Saclay University, Villejuif, France, Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France, Villejuif, France

Research Funding

Other

Background: Diet intervention in oncology is currently under investigation. Nevertheless, some cancer patients are increasingly using various diet interventions with the hope to optimize the anti-tumor response or to control the side effects of oncological treatment. Thus, well conducted prospective trials are required. In order to design such trials, we conducted a prospective study in order to estimate(a) the number of patients already using diet interventions on their own and (b) the percentage of patients who would agree to follow a restrictive diet in combination to antitumoral treatment within a prospective trial, if offered by their oncologist. Methods: Metastatic RCC patients seen at a single institution as outpatient clinic between April and May 2018, were offered to take part in an anonymous feasibility questionnaire. Questions included current treatment status for RCC, gender, height, and weight and explored (a) self diet restriction practices and (b) willingness to take part in trial(s) that would evaluate various diet interventions: fasting, ketogenic, vegetarian or vegan diets (each of them being explained). The proposed diet intervention was supposed to be for a minimum of 3 months. Results: Overall, 119 patients filled out the questionnaire. Median age was 61,5 years, 79(66.3%) were under systemic treatment. At time of data collection, 7.5% patients reported ketogenic diet practices, 0.9% fasting, none vegan or vegetarian diet. Regarding willingness to take part in “diet therapeutic trials”, 42.0% of patients claimed to agree to participate in a ketogenic diet trial, 29.4% of patients would agree to take part in a trial exploring fasting, 28.5% a vegetarian diet trial, and 14.2% of patients a vegan diet trial. No link between being under treatment and willingness to participate in trial was observed (p = 0.365). Conclusions: For the first time, we report feasibility of diet intervention within an homogenous population of patients with RCC. Almost half of patients are really keen in participating, with more interest for ketogenic diet and fasting. Such study raises the question of the feasibility of such trials, and obviously would make randomized trials very challenging.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 628)

DOI

10.1200/JCO.2019.37.7_suppl.628

Abstract #

628

Poster Bd #

H1

Abstract Disclosures

Similar Abstracts

First Author: Elaine Chang

Abstract

2023 ASCO Genitourinary Cancers Symposium

2022 Global patient survey: Reported experience of diagnosis, management, and burden of renal cell carcinomas.

First Author: Rachel H. Giles